Jazz Pharmaceuticals (JAZZ) Q2 2026 earnings review
Diversification Outruns the Patent Cliff
Jazz Pharmaceuticals delivered a record-breaking $1.2 billion in Q2 revenue (+16% YoY), proving its strategic pivot from legacy sleep medications to rare disease and oncology is working. The company completely erased last year's heavy IPR&D-driven losses, reversing to a robust $5.71 in Non-GAAP adjusted EPS. Strong launch execution for Zepzelca's frontline indication and the new glioma drug Modeyso allowed management to meaningfully raise full-year revenue guidance. While the loss of Zepzelca's second-line indication poses a setback, the broader portfolio's momentum and the imminent launch of Ziihera position Jazz firmly in growth territory.
🐂 Bull Case
Zepzelca surged 42% YoY to $106M on frontline maintenance adoption, and the Modeyso launch continues to accelerate, adding $48M in the quarter.
Despite looming generic threats, Xywav grew 13% YoY, adding 525 net patients and demonstrating the durability of its low-sodium and Idiopathic Hypersomnia (IH) advantages.
🐻 Bear Case
The company is formally withdrawing Zepzelca's second-line indication following the LAGOON trial, placing immense pressure on the first-line maintenance setting to carry the brand's growth.
Non-GAAP gross margins compressed from 92.7% a year ago to 92.1%, structurally weighed down by the higher royalty burdens attached to growing assets like Modeyso and Zepzelca.
⚖️ Verdict: 🟢
Bullish. The 16% revenue growth and material guidance raise confirm that Jazz's transition into a diversified rare disease powerhouse is succeeding faster than legacy revenues are eroding.
Key Themes
Zepzelca's First-Line Surge Masks Second-Line Pain
Zepzelca revenue accelerated dramatically, up 42% YoY to $106M. This growth is entirely fueled by the rapid uptake of its combination with atezolizumab in first-line extensive-stage small cell lung cancer (ES-SCLC). This frontline strength successfully offset the secular decline in the drug's second-line usage.
LAGOON Trial Forces Zepzelca Indication Withdrawal
In a tangible setback, management announced they will submit a labeling supplement in Q3 to voluntarily remove Zepzelca's second-line metastatic SCLC indication after reviewing data from the LAGOON trial. While frontline maintenance is unaffected, abandoning the original indication highlights clinical limits and permanently shrinks the drug's total addressable market.
Modeyso Launch Remains on a Steep Trajectory
The dordaviprone (Modeyso) launch continues accelerating. Revenue hit $48M in Q2, with over 600 total patients treated since its August 2025 launch. This early uptake validates the $905M Chimerix acquisition and supports management's conviction in a $500M+ peak U.S. sales opportunity.
Neuroscience Foundation Stays Rock Solid
The legacy foundation refuses to crack. Xywav posted $471M (+13% YoY) with 525 net patient adds, expanding to 17,125 active patients. Meanwhile, Epidiolex grew 16% YoY to $292M. The combined stability of these two assets provides the cash flow necessary to fund the massive oncology pivot.
Gross Margin Creep
Non-GAAP gross margin slightly decelerated to 92.1% (down from 92.7% in 25Q2). This compression is structurally tied to the company's successful diversification: as Modeyso and Zepzelca become larger portions of the revenue mix, their associated royalty obligations drag down the blended margin rate.
Ziihera PDUFA Imminent
The company is in immediate launch-readiness mode for Ziihera (zanidatamab) in HER2+ first-line GEA, with a PDUFA date of August 25, 2026. Armed with Priority Review and what management has called 'practice-changing' overall survival data, this represents Jazz's most significant near-term catalyst.
Continuous Dealmaking
Jazz recorded $77M in acquired IPR&D expense this quarter tied to a new preclinical collaboration with AbCellera and an asset purchase from Werewolf Therapeutics. This signals that management is actively utilizing its $824M in H1 operating cash flow to continuously replenish the early-stage pipeline.
Other KPIs
Stable and highly cash-generative. Strong commercial execution yielded massive cash generation in the first half of the year, enabling debt repayment ($1.0B in exchangeable senior notes paid off in June) while maintaining a $2.2B liquidity pile for future M&A.
Accelerating. Up 10% YoY from $310.3M in 25Q2, representing 28.4% of revenues. The absolute dollar increase reflects targeted marketing investments and compensation scaling to support the Modeyso launch and prepare for the imminent Ziihera rollout.
Guidance
Accelerating. Management meaningfully raised the range from the previous $4.25 - $4.50 billion. The new midpoint ($4.675B) implies robust ~9.5% YoY growth over FY25's $4.267B actuals, driven by outperformance in Xywav and the combined epilepsy/oncology franchises.
Accelerating. Raised from the prior $1,260 - $1,320 million range, indicating heavier near-term commercial investments to maximize the Ziihera launch and Zepzelca first-line expansion.
Stable. Maintained from prior guidance. This acknowledges that while top-line revenue is surging, the shifting product mix toward partnered/licensed assets (Zepzelca, Modeyso) will keep margins slightly below historical peaks.
Key Questions
Impact of LAGOON Data
With the decision to withdraw Zepzelca's second-line indication based on the LAGOON trial, what specific data points drove this decision, and does this read-through negatively to any other combination settings being explored?
H2 Oxybate Dynamics
You raised full-year guidance significantly, yet previously noted that multi-source oxybate generic competition would heat up in the second half of 2026. Have your assumptions on the speed or severity of generic erosion changed?
Ziihera Launch Trajectory
Assuming an August 25 FDA approval for Ziihera, how quickly do you expect NCCN guideline inclusion, and how much revenue contribution is embedded in the raised $4.60-$4.75B guidance for this specific asset in 2026?
Margin Floor
As higher-royalty products like Modeyso and Zepzelca drive an outsized portion of growth, what is the long-term structural floor for gross margins?